Formulation and evaluation of lansoprazole sublingual tablet

The objectives of present investigation is to improve the solubility and rate of dissolution of poorlyaqueous soluble drug lansoprazole by preparing solid dispersion with amphiphilic carrier Soluplus in 1:2concentration by using solvent evaporation method, solvent melting method and microwave oven method andselecting the best solid dispersion. The drug and excipient compatibility study of selected solid dispersion wasperformed by FTIR and DSC. These study showed no interaction in drug and carrier. The sublingual tablet representsan innovative drug delivery system, sublingual tablet of lansoprazole was formulated by incorporating selected soliddispersion with combination of novel superdisintegrants and taste maskers like Indion – 414 and Kyron T – 314 byusing direct compression method. The sublingual tablet showed the rapid disintegration within average 32 seconds.All the evaluations were performed and complies with the pharmacopoeial standards. The drug and excipientcompatibility study of lansoprazole sublingual tablet was also performed by FTIR and DSC. These study showed nointeraction in drug and excipients. The formulation F9 (12 % superdisintegrants) showed 98.42% of cumulative drugrelease within 8 min with zero order release pattern. These novel formulation lansoprazole sublingual tablet showedquick on set of action and may be found to be beneficial, convenient for pediatrics, geriatrics, and psychiatric patientsand patients with swallowing difficulties and in situations where water is not available.

PDF

___

[1] Garnett WR. Formulary forum lansoprazole : a proton pump inidbitor. Ann Pharmacother. 1996; 30(12): 1425-1436. [CrossRef]
[2] Matheson AJ, Jarvis B. Lansoprazole: an update of its place in the management of acid-related disorders. Drugs. 2001; 61(12): 1801-1833. [CrossRef]
[3] Richter JE, Kahrilas PJ, Sontag SJ, Kovacs TOG, Huang B, Pencyla JL. Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients. Am J Gastroenterol. 2001; 96(11): 3089-3098. [CrossRef]
[4] Population S. Lansoprazole for the prevention of recurrences of ulcer complicatons from long-term low-dose asprin use. N Engl J Med. 2002; 346(26): 2033-2038. [CrossRef]
[5] Malfertheiner P, Mégraud F, O’Morain C, Hungin APS, Jones R, Axon A, Graham DY, Tatya G. Current concepts in the management of helicobacter pylori infection - the maastricht 2-2000 consensus report. Aliment Pharmacol Ther. 2002; 16(2): 167-180. [CrossRef]
[6] Tolman KG, Sanders SW, Buchi KN, Karol MD, Jennings DE, Ringham GL. The effects of oral doses of lansoprazole and omeprazole on gastric ph. J Clin Gastroenterol. 1997; 24(2): 65-70. [CrossRef]
[7] Bind AK, Gnanarajan G, Kothiyal P. A review: sublingual route for systemic drug delivery. Int J Drug Res Tech. 2013; 3(2): 31-36.
[8] El-Samaligy MS, Afifi NN, Mahmoud EA. Increasing bioavailability of silymarin using a buccal liposomal delivery system: preparation and experimental design investigation. Int J Pharm. 2006; 308(1–2): 140-148. [CrossRef]
[9] Pawar PP, Ghorpade HS, Kokane BA. Sublingual route for systemic drug delivery. J Drug Deliv Ther. 2019; 8(6): 340–343. [CrossRef]
[10] Price TM, Blauer KL, Hansen M, Stanczyk F, Lobo R, Bates GW. Single-dose pharmacokinetics of sublingual versus oral administration of micronized 17β-estradiol. Obstet Gynecol Surv. 1997; 89(3): 340-345. [CrossRef]
[11] Narang N, Sharma J. Sublingual mucosa as a route for systemic drug delivery. Int J Pharm Pharm Sci. 2011; 3(2): 18–22.
[12] Singh DH, Roychowdhury S, Varma P, Bhandari V. A review on recent advances of enteric coating. IOSR J Pharm. 2012; 2(6): 05-11.
[13] Nikghalb LA, Singh G, Singh G, Kahkeshan KF. Solid dispersion: methods and polymers to increase the solubility of poorly soluble drugs. J Appl Pharm Sci. 2012; 2(10): 170-175. [CrossRef]
[14] Baka E, Comer JEA, Takács-Novák K. Study of equilibrium solubility measurement by saturation shake flask method using hydrochlorothiazide as model compound. J Pharm Biomed Anal. 2008; 46(2): 335-341. [CrossRef]
[15] Garg T. An approach for improvement of the water solubility of gliclazide in solid dispersion with. Int J Pharm Sci Res. 2011; 2(6): 1600-1602. [CrossRef]
[16] Lu Y, Guo T, Qi J, Zhang J, Wu W. Enhanced dissolution and stability of lansoprazole by cyclodextrin inclusion complexation: preparation, characterization, and molecular modeling. AAPS PharmSciTech. 2012; 13(4): 1222–1229. [CrossRef]
[17] Patil OA, Patil IS, Mane RU, Randive DS, Bhutkar MA, Bhinge SD. Formulation optimization and evaluation of cefdinir nanosuspension using 23 factorial design. Marmara Pharm J. 2018; 22(4): 587–598. [CrossRef]
[18] Bhagat S, Rodrigues C, Keny RV. Design and development of rapid release mouth disintegrating terbutaline sulphate tablets - a comparative evaluation of superdisintegrants and their combinations. Int J Res Chem. 2014; 4(3): 586–594.
[19] Mohanachandran PS, Sindhumol PG, Kiran TS. Superdisintegrants: an overview. Int J Pharm Sci Rev Res. 2011; 6(1): 105–109.
[20] Sah S, Badola A, Kothiyal P. Sublingual tablets : an overview. Indian J Pharm Biomed Res. 2016; 4(2): 20–26.
[21] Bookya P, Raparla R, Sriramula S. Formulation and evaluation of fast dissolving tablets of captopril. J Pharm Res. 2014; 8(7): 963–968.
[22] Chaudhari K, Jadhao U, Chaudhari C, Thakare V, Tekade B, Chaudhari C. Formulation and evaluation of fast dissolving sublingual tablets of amlodipine besylate. Der Pharmac Sin. 2014; 5(4): 1-9.
[23] Mohan K, Sai R, Sudheer M, Kumar K, Kumar A, Sekhar R, Nagarjuna S. New uv-spectrophotometric method for the determination of lansoprazole in pharmaceutical dosage form and its application to protein binding study. J Pharm Res. 2011; 4(6): 1586-1587.
[24] Kavitha R, Sathali AH. Enhancement of solubility of repaglinide by solid dispersion technique. Int J Chem Sci. 2012; 10(1): 377–390.
[25] Neha A, Singh I, Sharma M, Tarun G. An approach for improvement of the water solubility of nimesulide in solid dispersion with peg 4000. IOSR J Pharm. 2012; 2(2): 153-154.
[26] Nasir AS. Jain AM, Bari MM, Chavan RB, Barhate SD. New dimensions to solid dispersion. Indo Am J Pharm Res. 2013; 3(4): 3246–3255.
[27] Kurnool AN, Vijay Kumar BS, Chilkwar RN, Jagdeesha SE. Formulation and evaluation of sublingual drug delivery system containing anti-ulcerative agent. World J Pharm Pharm Sci. 2015; 4(5): 890-899.
[28] Shah NH, Nagar BJ, Sheorey SD, Agrawal V, Shah JM. Formulation and evaluation of orodispersible labetalol tablet for hypertensive crisis. J Drug Deliv Ther. 2013; 3(6): 106-112.
[29] Indian Pharmacopoeia, sixth ed., India 2010.